Achieving lipid goals in real life: the Dutch DISCOVERY Study
2005; Wiley; Volume: 59; Issue: 12 Linguagem: Inglês
10.1111/j.1368-5031.2005.00708.x
ISSN1742-1241
AutoresA. F. E. Bots, John J.P. Kastelein,
Tópico(s)Pharmaceutical Economics and Policy
ResumoInternational Journal of Clinical PracticeVolume 59, Issue 12 p. 1387-1394 Achieving lipid goals in real life: the Dutch DISCOVERY Study A. F. E. Bots, Corresponding Author A. F. E. Bots Zuider Hoed General Practice,1's-Hertogenbosch, Academic Medical Center,2Amsterdam, the Netherlands *Dr A. F. E. Bots, Hinthamereinde 13, 5211 PL 's-Hertogenbosch, the NetherlandsTel.: + 31 7361 34450Email: [email protected]Search for more papers by this author 1 J. J. P. Kastelein, J. J. P. Kastelein Zuider Hoed General Practice,1's-Hertogenbosch, Academic Medical Center,2Amsterdam, the NetherlandsSearch for more papers by this author 2 on behalf of the discovery netherlands investigators, on behalf of the discovery netherlands investigators Zuider Hoed General Practice,1's-Hertogenbosch, Academic Medical Center,2Amsterdam, the NetherlandsSearch for more papers by this author A. F. E. Bots, Corresponding Author A. F. E. Bots Zuider Hoed General Practice,1's-Hertogenbosch, Academic Medical Center,2Amsterdam, the Netherlands *Dr A. F. E. Bots, Hinthamereinde 13, 5211 PL 's-Hertogenbosch, the NetherlandsTel.: + 31 7361 34450Email: [email protected]Search for more papers by this author 1 J. J. P. Kastelein, J. J. P. Kastelein Zuider Hoed General Practice,1's-Hertogenbosch, Academic Medical Center,2Amsterdam, the NetherlandsSearch for more papers by this author 2 on behalf of the discovery netherlands investigators, on behalf of the discovery netherlands investigators Zuider Hoed General Practice,1's-Hertogenbosch, Academic Medical Center,2Amsterdam, the NetherlandsSearch for more papers by this author First published: 18 November 2005 https://doi.org/10.1111/j.1368-5031.2005.00708.xCitations: 15 Dr A. F. E. Bots has no conflicts of interest. Dr J. J. P. Kastelein is a professor of medicine and chairs the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands. He has received research support and speaker fees from AstraZeneca. The DISCOVERY Netherlands trial was conducted in 152 primary care physician practices in the Netherlands. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Summary DISCOVERY Netherlands was an open-label, randomised, multicentre study (D3560/L00003) designed to compare the effects of rosuvastatin with those of atorvastatin, simvastatin or pravastatin on low-density lipoprotein cholesterol (LDL-C) goal achievement in a primary care setting. Patients (n = 1215) with type IIa or type IIb hypercholesterolaemia and cardiovascular risk of >20% or a history of coronary heart or other atherosclerotic vascular disease were randomised to receive treatment with rosuvastatin 10 mg (n = 621), atorvastatin 10 mg (n = 189), simvastatin 20 mg (n = 194) or pravastatin 40 mg (n = 211) for 12 weeks. Significantly, more patients achieved 1998 and 2003 European LDL-C goals with rosuvastatin than with other statins after 12 weeks (p < 0.001). Rosuvastatin reduced LDL-C and total cholesterol levels significantly more than other statins, both in patients who were statin-naïve and in patients who had received previous statin treatment (p < 0.05). All treatments were similarly well tolerated. In conclusion, greater reductions in LDL-C were achieved with rosuvastatin compared with atorvastatin, simvastatin and pravastatin, enabling more patients to achieve European LDL-C goals. References 1 Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434–503. 2 Simoons ML, Casparie AF. Behandeling en preventie van coronaire hartziekten door verlaging van de serumcholesterolconcentratie; derde consensus 'Cholesterol'. Ned Tijdschr Geneeskd 1998; 142: 2092–101. 3 Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97. 4 De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10 (Suppl. 1): S2–78. 5 EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–72. 6 Mantel-Teeuwisse AK, Verschuren WM, Klungel OH et al. Undertreatment of hypercholesterolaemia: a population-based study. Br J Clin Pharmacol 2003; 55: 389–97. 7 Shepherd J, Hunninghake DB, Barter P et al. Guidelines for lowering lipids to reduce coronary heart disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003; 91: 11C–9C. 8 Jones PH, Davidson MH, Stein EA et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60. 9 Schuster H, Barter PJ, Stender S et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705–12. 10 Strandberg TE, Feely J, Sigurdsson EL. DISCOVERY Study Group. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin Ther 2004; 26: 1821–33. 11 Kritharides L. Reducing low-density lipoprotein cholesterol – treating to target and meeting new European goals. Eur Heart J Suppl 2004; 6 (Suppl. A): A12–8. 12 Olsson AG, Pears J, Mckellar J et al. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88: 504–8. 13 Olsson AG, Istad H, Luurila O et al. Rosuvastatin Investigators Group. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002; 144: 1044–51. 14 Brown WV, Bays HE, Hassman DR et al. Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002; 144: 1036–43. 15 Alsheikh AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice. Circulation 2005; 111: 3051–7. 16 Grundy SM. The issue of statin safety. Where do we stand? Circulation 2005; 111: 3016–9. 17 Department of Health and Human Services. Re: Docket no. 2004P-0113/CP1. Available at: http://www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf (accessed July 13 2005). Citing Literature Volume59, Issue12December 2005Pages 1387-1394 ReferencesRelatedInformation
Referência(s)